High Tech Pharm Co. Ltd Total Liabilities
High Tech Pharm Co. Ltd total liabilities. Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has total liabilities worth ₩12.57 Billion KRW (≈ $8.52 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of High Tech Pharm Co. Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of High Tech Pharm Co. Ltd (2014–2024)
Total liabilities of High Tech Pharm Co. Ltd from 2014 to 2024. This chart illustrates how High Tech Pharm Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore High Tech Pharm Co. Ltd (106190) long-term investment share to see how much of total assets are deployed in long-term investments.
High Tech Pharm Co. Ltd Competitors by Total Liabilities
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titanium Oyj
HE:TITAN
|
Finland | €3.98 Million |
|
Scully Royalty Ltd
F:MB01
|
Germany | €127.77 Million |
|
Complex Micro Interconnection Co. Ltd.
TW:6835
|
Taiwan | NT$1.96 Billion |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
Turkey | TL1.88 Billion |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
Malaysia | RM434.75 Million |
|
Finger Inc.
KQ:163730
|
Korea | ₩19.89 Billion |
|
Peninsula Energy Ltd
AU:PEN
|
Australia | AU$44.01 Million |
|
Klingon Aerospace Inc
TW:1529
|
Taiwan | NT$1.29 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down High Tech Pharm Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 106190 total assets.
Liquidity & Leverage Metrics
High Tech Pharm Co. Ltd Total Liabilities Ratios Explained
High Tech Pharm Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how High Tech Pharm Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual total liabilities of High Tech Pharm Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩20.35 Billion ≈ $13.79 Million |
-27.48% |
| 2023-12-31 | ₩28.06 Billion ≈ $19.02 Million |
-13.02% |
| 2022-12-31 | ₩32.26 Billion ≈ $21.86 Million |
+11.05% |
| 2021-12-31 | ₩29.05 Billion ≈ $19.69 Million |
-12.76% |
| 2020-12-31 | ₩33.30 Billion ≈ $22.57 Million |
+0.49% |
| 2019-12-31 | ₩33.14 Billion ≈ $22.46 Million |
+11.77% |
| 2018-12-31 | ₩29.65 Billion ≈ $20.09 Million |
+75.41% |
| 2017-12-31 | ₩16.90 Billion ≈ $11.46 Million |
-1.33% |
| 2016-12-31 | ₩17.13 Billion ≈ $11.61 Million |
+20.44% |
| 2015-12-31 | ₩14.23 Billion ≈ $9.64 Million |
-2.10% |
| 2014-12-31 | ₩14.53 Billion ≈ $9.85 Million |
-- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.